| Pharmaceutical Information |
| Drug Name |
Temsirolimus |
| Drug ID |
BADD_D02151 |
| Description |
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007. |
| Indications and Usage |
For the treatment of renal cell carcinoma (RCC). Also investigated for use/treatment in breast cancer, lymphoma (unspecified), rheumatoid arthritis, and multiple myeloma. |
| Marketing Status |
approved |
| ATC Code |
L01EG01 |
| DrugBank ID |
DB06287
|
| KEGG ID |
D06068
|
| MeSH ID |
C401859
|
| PubChem ID |
6918289
|
| TTD Drug ID |
D0ES1Q
|
| NDC Product Code |
0008-1179; 65219-200; 16729-223; 68254-6237; 78848-002; 65727-047 |
| UNII |
624KN6GM2T
|
| Synonyms |
temsirolimus | rapamycin, 42-(3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate) | CCI 779 | CCI-779 | Torisel |
|
| Chemical Information |
| Molecular Formula |
C56H87NO16 |
| CAS Registry Number |
162635-04-3 |
| SMILES |
CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)
C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
